Soligenix, Inc. (NASDAQ:SNGX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus target price of $6.25 for the company and are predicting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also assigned Soligenix an industry rank of 70 out of 257 based on the ratings given to its competitors.
A number of equities research analysts recently weighed in on the stock. Maxim Group set a $4.00 price target on shares of Soligenix and gave the stock a “buy” rating in a research note on Thursday. ValuEngine raised shares of Soligenix from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.
In other news, Director Mark E. Pearson bought 170,000 shares of the stock in a transaction on Wednesday, October 17th. The stock was purchased at an average price of $1.16 per share, with a total value of $197,200.00. Following the completion of the purchase, the director now owns 2,500,000 shares of the company’s stock, valued at $2,900,000. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.03% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Soligenix by 46.5% in the third quarter. Vanguard Group Inc. now owns 339,732 shares of the biopharmaceutical company’s stock valued at $639,000 after purchasing an additional 107,875 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Soligenix in the third quarter valued at approximately $188,000. Finally, Virtu Financial LLC bought a new stake in Soligenix in the third quarter valued at approximately $116,000. 9.13% of the stock is owned by hedge funds and other institutional investors.
Shares of SNGX remained flat at $$0.97 on Friday. 56,769 shares of the company were exchanged, compared to its average volume of 177,041. Soligenix has a twelve month low of $0.91 and a twelve month high of $3.70.
Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.11). The business had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.40 million. Soligenix had a negative net margin of 146.45% and a negative return on equity of 144.47%. On average, analysts predict that Soligenix will post -0.62 EPS for the current year.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
See Also: What is a Futures Contract?
Get a free copy of the Zacks research report on Soligenix (SNGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.